Left Menu
Development News Edition

Sun Pharma initiates phase two clinical trial on AQCH as potential treatment for COVID-19 patients

Sun Pharmaceutical Industries has started phase two clinical trial on AQCH, a phytopharmaceutical (plant-derived) drug for the treatment of COVID-19.

ANI | Mumbai (Maharashtra) | Updated: 05-06-2020 13:01 IST | Created: 05-06-2020 13:01 IST
Sun Pharma initiates phase two clinical trial on AQCH as potential treatment for COVID-19 patients
The company has 42 manufacturing facilities across six continents.. Image Credit: ANI

Sun Pharmaceutical Industries has started phase two clinical trial on AQCH, a phytopharmaceutical (plant-derived) drug for the treatment of COVID-19. The company got approval from Drugs Controller General of India (DCGI) for conducting phase two clinical trial in April. The clinical trial will be conducted across 12 centres in India on 210 patients with a duration of 10 days.

The results of the clinical trial are expected by October. Human safety study of AQCH has already been completed and the drug has been found safe at the recommended dose for phase two study. Managing Director Dilip Shanghvi said it is the first phytopharmaceutical drug approved for clinical trials by the DCGI as a potential treatment for COVID-19.

"AQCH has shown anti-SARS-CoV-2 effects in in-vitro studies conducted in collaboration with the International Centre for Genetic Engineering and Biotechnology (ICGEB) in Italy. These results combined with information on the mechanism of action through in-vitro and small animal studies give us the confidence to evaluate this potential treatment option for COVID-19 patients," he said in a statement on Friday. AQCH, which is being developed for dengue, has shown a broad antiviral effect in vitro studies and hence is being tested as a potential treatment option for COVID-19. Since 2016, Sun Pharma has been working closely with DBT-ICGEB under the leadership of Dr Navin Khanna and CSIR-IIIM under the leadership of Dr Ram Vishwakarma to develop a phytopharmaceutical drug for dengue.

The work on the evaluation of plant-derived drugs for the treatment of dengue started in 2007 under the auspices of the Department of Biotechnology's (DBT) Task Force on Medicinal and Aromatic Plants. Renu Swarup, Secretary of Department of Biotechnology, Ministry of Science and Technology, said: "Our efforts to develop a safe, effective and affordable drug against dengue started about 13 years ago. The collaborating team quickly initiated studies for the development of a drug against COVID-19. I wish the collaborating team success in the conduct of the clinical trial against COVID-19 and for the development of phytopharmaceutical drugs against other infectious diseases."

Shekhar C Mande, Director General of Council of Scientific and Industrial Research (CSIR), said: "CSIR has had a long-standing association with the pharmaceutical industry in India and welcomes this collaboration with Sun Pharma in taking forward AQCH into clinical trials for Covid-19 patients. This collaboration aligns with our scientific rationale for the quickest way to develop drugs against SARS-CoV-2." Sun Pharma is the world's fourth-largest speciality generic pharmaceutical company and India's top pharmaceutical company. Delivering products for customers and patients in over 100 countries, its global presence is supported by manufacturing facilities spread across six continents which are approved by multiple regulatory agencies. (ANI)


TRENDING

OPINION / BLOG / INTERVIEW

Pride in the time of coronavirus: a welcome move online?

This year is different in many ways not least as celebrations are also taking place against the dramatic backdrop of a global health crisis and a resurgence in grassroots activism following the death of George Floyd in Minneapolis. ...

COVID-19: Weighing up the benefits and limitations of edtech platforms

Edtech companies shouldnt focus on merely pushing contents, but to provide an interactive, effective teaching and learning environment. ...

Shipping industry's COVID-19 resilience test could boost digitalization

The push towards digitalization in shipping industry was already happening and has been further accelerated by the pandemic as current practices are not tenable under present circumstances and would definitely not be in the future....

Health is pure science but why objectivity eludes WHO

We certainly need a global body to coordinate responses against health emergencies. However, this sheer need of humanity on this planet should not be milked by the World Organization WHO to overshadow constructive criticism and call for ref...

Videos

Latest News

New French PM Castex warns about economic crisis, says priorities to change

Frances new prime minister, Jean Castex, warned on Friday that the coronavirus pandemic was not over yet and an economic crisis was already making itself felt, as he took the helm of President Emmanuel Macrons government. The economic crisi...

European stocks slide as surge in virus cases hits rebound hopes

European stocks fell on Friday after gaining ground during the week as a surge in U.S. coronavirus cases made investors less optimistic about prospects for a rebound in the global economy.After opening largely flat, the pan-European STOXX 6...

J-K: Sopore Police takes cognizance of misuse of social media, FIR registered

A case has been registered by Sopore Police against several social media users for allegedly spreading false propaganda against the government. Taking serious note of misuse of social media platforms, Sopore Police has registered a case aga...

Chandigarh's COVID-19 tally reaches 454

Four more people tested positive for coronavirus in Chandigarh on Friday, taking the tally in the city to 454. The new patients are two members of a family in Khudda Lahora area, a 67-year-old woman from Sector 15 and a 63-year-old man from...

Give Feedback